Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Epidemiology, Biomarkers & Prevention
Cancer Epidemiology, Biomarkers & Prevention
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • CEBP Focus Archive
    • Meeting Abstracts
    • Progress and Priorities
    • Collections
      • COVID-19 & Cancer Resource Center
      • Disparities Collection
      • Editors' Picks
      • "Best of" Collection
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Informing Public Health Policy
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Commentaries

Improving the Process of Screening for Medical Financial Hardship in Oncology Practice

K. Robin Yabroff, Cathy J. Bradley and Ya-Chen Tina Shih
K. Robin Yabroff
1Surveillance & Health Equity Science Department, American Cancer Society, Atlanta, Georgia.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for K. Robin Yabroff
  • For correspondence: robin.yabroff@cancer.org
Cathy J. Bradley
2University of Colorado Comprehensive Cancer Center and Colorado School of Public Health, Aurora, Colorado.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ya-Chen Tina Shih
3Section of Cancer Economics and Policy, Department of Health Services Research, University of Texas MD Anderson Cancer Center, Houston, Texas.
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • ORCID record for Ya-Chen Tina Shih
DOI: 10.1158/1055-9965.EPI-21-0111 Published April 2021
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Medical financial hardship, including problems paying medical bills, distress, and forgoing care because of cost, is increasingly common among patients receiving cancer treatment and cancer survivors across the economic spectrum. Little is known, however, about provider practices for identifying patients who experience financial hardship and the strategies for mitigating hardship and addressing patient needs. In this editorial, we discuss a study of practices within the NCI Community Oncology Research Program. McLouth and colleagues found disparities in the use of screening and financial navigation and reliance on inadequate screening methods. To address these disparities, we emphasize the importance of comprehensive and ongoing financial hardship screening throughout the course of cancer treatment and survivorship care, as well as the necessity of accompanying counseling, navigation, and referrals. We also recommend key attributes of screening tools and a process for systematic implementation within clinical practice. With adverse health and economic consequences of the COVID-19 pandemic disproportionately affecting people who are racial or ethnic minorities, uninsured or underinsured, or living in poverty, the need to address medical financial hardship is more urgent than ever, to ensure that all people have an equal opportunity for high quality cancer treatment and survival.

See related article by McLouth et al., p. 669

For the past several decades, advances in cancer treatment are accompanied by large and growing price tags (1), making cancer one of the most expensive conditions to treat in the United States (2). Along with cost of treatment, the economic burden of cancer to patients and their families is also growing, as health insurers require greater patient cost-sharing for health care, and increases in the number of cancer survivors without health insurance coverage (3). Medical financial hardship, including problems paying medical bills, distress, and forgoing care because of cost (4), is more common among adult cancer survivors than similar adults without a cancer history (5). Financial hardship adversely affects health by lowering quality of life (6) and increasing mortality risk (7). Financial hardship is most common among populations who have historically experienced challenges with accessing cancer care, including people who have low incomes, are uninsured/underinsured, or are racial/ethnic minorities (8), but financial hardship is becoming commonplace across the economic spectrum. Advances in expensive cancer treatments threaten to widen disparities in access to care based on the ability to pay. Thus, understanding how institutions and providers identify patients experiencing financial hardship and the strategies used to mitigate hardship and address patient needs are increasingly important.

Several surveys of cancer care providers have explored practices related to financial hardship screening, navigation, and counseling (9–11). For example, a survey of NCI comprehensive cancer centers found that nearly all reported some form of financial screening (10). Another survey of National Comprehensive Cancer Network (NCCN) member institutions, most of which are comprehensive cancer centers, found that the majority screen for financial hardship, commonly with the NCCN Distress Thermometer (9). In this issue of Cancer Epidemiology Biomarkers & Prevention, McLouth and colleagues describe practices for screening and addressing financial hardship in community oncology practices, where most patients with cancer are treated (12). Their study of 221 community oncology practices affiliated with the NCI Community Oncology Research Program (NCORP) reported that about three-quarters of them have a screening process for their patients and half have cancer-specific financial navigators. The methods of screening and availability of navigation services varied widely. Practices treating a larger proportion of minority patients were less likely to screen for financial concerns or have financial navigators or counselors than those practices treating fewer minority patients. Practices serving more patients with Medicaid coverage, the state and federal program for low-income populations, were more likely to conduct screening, but not any more likely to offer navigation services. This study identifies important disparities in financial hardship screening and/or navigation for practices serving larger minority or Medicaid-insured patients, who may be at greater risk of hardship and adverse outcomes. These findings also highlight the need to optimize and standardize financial hardship screening, counseling, and navigation, as well as efforts to mitigate hardship.

The most common methods for screening in NCORP practices appear to focus on whether patients have health insurance coverage. This approach is inadequate because even privately insured patients and survivors experience financial hardship (5). Insurance coverage can also be unstable, especially for adults with lower income, Medicaid coverage (13), or loss of employment-based private coverage. Reliance on the presence of insurance coverage as a screening mechanism will surely miss insured patients with hardship. This observation raises an important, but somewhat neglected topic—the difference between financial counseling and navigation. Specifically, financial counselors are often employed to minimize uncompensated care for providers and may not function as financial navigators whose primary goal is minimizing patients' financial hardship.

Some NCORP practices use screening tools like the NCCN distress thermometer, which has a list of practical problems, including a single item for “insurance/financial” problems. There are many other tools for identifying patients with financial hardship and/or social needs (14). Some were tailored for patients with cancer, such as the comprehensive score for financial toxicity (COST; ref. 15) and economic strain and resilience in cancer (ENRICh; ref. 16) instruments, whereas others, such as the protocol for responding to and assessing patient assets, risks, and experiences (PRAPARE) tool, are not condition specific, but developed for implementation in clinical practice in federally qualified health centers. Table 1 highlights selected features of these tools. Importantly, any tool for identifying medical financial hardship must be used as part of a process that begins with screening, connects patients with relevant services, and ensures that needs are met. Screening that identifies specific domains of medical financial hardship, material (e.g., problems paying medical bills), psychologic (e.g., distress), and/or behavioral (e.g., delaying or forgoing care because of cost), or other social needs, such as food insecurity or housing instability, can guide interventions. Low-income, minority, or uninsured/underinsured patients can be especially vulnerable if they receive treatment from institutions or facilities that conduct only financial screening without offering or referring for additional needed services.

View this table:
  • View inline
  • View popup
Table 1.

Characteristics of selected tools for financial hardship screening.

In Table 2, we recommend key attributes of tools for medical financial hardship screening, such as ease of their use in clinical settings and their utility for guiding interventions. We also suggest inclusion of multiple measures of economic stability and social needs, such as health insurance coverage, employment, household income, and debt burden, as well as food insecurity, housing instability, transportation challenges, and social support. Multiple measures of medical financial hardship within material, psychologic, and behavioral domains are recommended. Patient clinical and demographic characteristics may be available from existing electronic health records (EHR) and could be used to prepopulate a screening tool, allowing for integration with clinical workflows. If these data are not available, they should be collected as part of screening.

View this table:
  • View inline
  • View popup
Table 2.

Key attributes of financial hardship screening tools.

How might a financial hardship screening tool be implemented in clinical practice to systematically identify patients with financial hardship and ensure that their needs are addressed? We suggest adapting the well-accepted “5′As” approach for successful intervention in tobacco cessation: ask, advise, assess, assist, and arrange (17). In this context, patients are asked whether they are experiencing medical financial hardship, and if so, navigators, social workers, or other providers advise and counsel, assess the current treatment plan, assist treatment plan adjustment or identify sources of financial assistance, and arrange for referrals for additional services (Fig. 1). This process must occur iteratively because factors underlying the risk of medical financial hardship (e.g., lack of insurance coverage, unemployment, low income, and social needs) can change throughout the course of treatment and survivorship care. Yet, even in NCCN member institutions, only 56% reported screening for financial hardship more than once (9). It is critical that this process is documented in the medical record to allow for ongoing assessment and evaluation (18). Further underscoring the need for repeated screening, a study conducted within NCORP practices found that one-quarter of newly diagnosed patients with metastatic colorectal cancer reported major financial hardship (defined as major debt, loans, selling or refinancing house, or 20% decline in income) within 3 months of receiving treatment and by 12 months, nearly three-quarters reported major financial hardship (19), demonstrating the cumulative risk of financial hardship as treatment progresses. Strikingly, more than 95% of these patients were insured. Most of these patients would not have been identified by financial hardship screening practices that either rely on whether patients have health insurance coverage or on a one-time hardship screening at treatment initiation.

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Model for implementation of financial screening in clinical practice. Figure contains a model for implementation of financial screening adapted from the “5′As” approach for successful intervention in tobacco cessation: ask, advise, assess, assist, and arrange (17). In this context, patients are asked whether they are experiencing medical financial hardship, and if so, navigators, social workers, or providers advice and counsel, assess the current treatment plan, assist treatment plan adjustment or identify sources of financial assistance, and arrange for referrals for additional services.

McLouth and colleagues discussed the need for stakeholder engagement from patients and informal caregivers to providers and policy makers, in efforts to identify and address patient medical financial hardship (12). They also acknowledged state and federal policies as central to these efforts. We wholeheartedly agree. In the absence of state and federal policies that ensure comprehensive health insurance coverage options and equitable access to affordable, timely, and effective care, patients, their families, and their treating institutions are left on their own to minimize financial burden. Interventions focused on patient navigation may be best when partnered with multi-level interventions that include policy changes. Such interventions must be both scalable and sustainable in routine practice. We recommend that evaluations of interventions to mitigate financial hardship collect detailed information about the cost, as well as budget impact (20) from the perspective of a practice or health system to inform questions of sustainability. Finally, any solutions must first focus on practices serving minority and underserved populations, who were less likely to screen for medical financial hardship and have cancer-specific navigation.

Cancer is frequently an unexpected diagnosis and its treatment can result in thousands of dollars in out-of-pocket expenses and medical debt for patients and their families, even if they have health insurance coverage (21). In 2017, nearly 40% of American families reported that they could not cover an unexpected expense of $400 (22). The COVID-19 pandemic, which led to widespread unemployment and loss of not only income, but access to employer-sponsored health insurance coverage, has exacerbated the economic challenges that many families face. We expect medical financial hardship to become even more prevalent in 2021 and beyond, especially because people who are racial or ethnic minorities, uninsured or underinsured, or living in poverty have disproportionately experienced adverse effects of the COVID-19 pandemic. Efforts to identify and address medical financial hardship are more urgent than ever, for state and federal policymakers and all institutions treating patients with cancer, to ensure that all have an equitable opportunity to treat and survive cancer.

Authors' Disclosures

Y.-C.T. Shih reports personal fees from Pfizer and AstraZeneca outside the submitted work. No disclosures were reported by the other authors.

Footnotes

  • Cancer Epidemiol Biomarkers Prev 2021;30:593–6

  • Received January 25, 2021.
  • Revision received February 17, 2021.
  • Accepted February 17, 2021.
  • Published first April 2, 2021.
  • ©2021 American Association for Cancer Research.

References

  1. 1.↵
    1. Shih YC,
    2. Smieliauskas F,
    3. Geynisman DM,
    4. Kelly RJ,
    5. Smith TJ
    . Trends in the cost and use of targeted cancer therapies for the privately insured nonelderly: 2001 to 2011. J Clin Oncol 2015;33:2190–6.
    OpenUrlAbstract/FREE Full Text
  2. 2.↵
    1. Soni A
    . Trends in the five most costly conditions among the U.S. Civilian Noninstitutionalized Population, 2002 and 2012. Available from: http://www.meps.ahrq.gov/mepsweb/data_files/publications/st470/stat470.shtml.
  3. 3.↵
    1. Moss HA,
    2. Han X,
    3. Yabroff KR,
    4. Chino J,
    5. Chino F
    . Declines in health insurance among cancer survivors since the 2016 US elections. Lancet Oncol 2020;21:e517.
    OpenUrl
  4. 4.↵
    1. Yabroff KR,
    2. Bradley C,
    3. Shih YT
    . Understanding financial hardship among cancer survivors in the United States: strategies for prevention and mitigation. J Clin Oncol 2020;38:292–301.
    OpenUrl
  5. 5.↵
    1. Zheng Z,
    2. Jemal A,
    3. Han X,
    4. Guy GP,
    5. Li C,
    6. Davidoff AJ,
    7. et al.
    Medical financial hardship among cancer survivors in the United States. Cancer 2019;125:1737–47.
    OpenUrl
  6. 6.↵
    1. Lathan CS,
    2. Cronin A,
    3. Tucker-Seeley R,
    4. Zafar SY,
    5. Ayanian JZ,
    6. Schrag D
    . Association of financial strain with symptom burden and quality of life for patients with lung or colorectal cancer. J Clin Oncol 2016;34:1732–40.
    OpenUrlAbstract/FREE Full Text
  7. 7.↵
    1. Ramsey SD,
    2. Bansal A,
    3. Fedorenko CR,
    4. Blough DK,
    5. Overstreet KA,
    6. Shankaran V,
    7. et al.
    Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol 2016;34:980–6.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    1. Yabroff KR,
    2. Zhao J,
    3. Han X,
    4. Zheng Z
    . Prevalence and correlates of medical financial hardship in the USA. J Gen Intern Med 2019;34:1494–502.
    OpenUrl
  9. 9.↵
    1. Khera N,
    2. Sugalski J,
    3. Krause D,
    4. Butterfield R,
    5. Zhang N,
    6. Stewart FM,
    7. et al.
    Current practices for screening and management of financial distress at NCCN member institutions. J Natl Compr Canc Netw 2020;18:825–31.
    OpenUrl
  10. 10.↵
    National Cancer Institute. Survey of financial navigation services and research summary. 2020. https://cancercontrol.cancer.gov/research-emphasis/financial-hardship. Accessed March 3, 2021.
  11. 11.↵
    1. Bowen Benson AI,
    2. Boehmer L,
    3. Shivakumar L,
    4. Trosman JR,
    5. Weldon CB,
    6. Hahn EA,
    7. et al.
    Resource and reimbursement barriers to comprehensive cancer care (CCC) delivery: an Association of Community Cancer Centers (ACCC) survey research analysis. J Clin Oncol 38:29s, 2020 (suppl; abstr 31).
  12. 12.↵
    1. McLouth LE,
    2. Nightingale CL,
    3. Dressler EV,
    4. Snavely AC,
    5. Hudson MF,
    6. Unger JM,
    7. et al.
    Current practices for screening and addressing financial hardship within the National Cancer Institute's Community Oncology Research Program. Cancer Epidemiol Biomarkers Prev 2021;30:669–75.
    OpenUrlAbstract/FREE Full Text
  13. 13.↵
    1. Short PF,
    2. Graefe DR,
    3. Schoen C
    . Churn, churn, churn: how instability of health insurance shapes America's uninsured problem. Issue Brief (Commonw Fund) 2003;688:1–16. PMID: 14621666.
    OpenUrl
  14. 14.↵
    1. Henrikson NB,
    2. Blasi PR,
    3. Dorsey CN,
    4. Mettert KD,
    5. Nguyen MB,
    6. Walsh-Bailey C,
    7. et al.
    Psychometric and pragmatic properties of social risk screening tools: a systematic review. Am J Prev Med 2019;57:S13–S24.
    OpenUrl
  15. 15.↵
    1. de Souza JA,
    2. Yap BJ,
    3. Hlubocky FJ,
    4. Wroblewski K,
    5. Ratain MJ,
    6. Cella D,
    7. et al.
    The development of a financial toxicity patient-reported outcome in cancer: the COST measure. Cancer 2014;120:3245–53.
    OpenUrlCrossRefPubMed
  16. 16.↵
    1. Smith GL,
    2. Volk RJ,
    3. Lowenstein LM,
    4. Peterson SK,
    5. Rieber AG,
    6. Checka C,
    7. et al.
    ENRICH: validating a multidimensional patient-reported financial toxicity measure. J Clin Oncol 2019;37:153.
    OpenUrlCrossRefPubMed
  17. 17.↵
    Agency for Healthcare Research and Quality . Five major steps to intervention (the "5 A's"). Available from: https://www.ahrq.gov/prevention/guidelines/tobacco/5steps.html.
  18. 18.↵
    1. Bradley CJ,
    2. Yabroff KR,
    3. Zafar SY,
    4. Shih YT
    . Time to add screening for financial hardship as a quality measure? CA Cancer J Clin 2020 Nov 23. doi: 10.3322/caac.21653. Epub ahead of print. PMID: 33226648.
  19. 19.↵
    1. Shankaran V,
    2. Unger JM,
    3. Darke A,
    4. Suga JM,
    5. Wade JL,
    6. Kourlas P,
    7. et al.
    Cumulative incidence of financial hardship in metastatic colorectal cancer patients: Primary endpoint results for SWOG S1417CD. J Clin Oncol 2020;38:7010.
    OpenUrl
  20. 20.↵
    1. Mauskopf JA,
    2. Sullivan SD,
    3. Annemans L,
    4. Caro J,
    5. Mullins CD,
    6. Nuijten M,
    7. et al.
    Principles of good practice for budget impact analysis: report of the ISPOR Task Force on good research practices–budget impact analysis. Value Health 2007;10:336–47.
    OpenUrlCrossRefPubMed
  21. 21.↵
    1. Banegas MP,
    2. Guy GP Jr.,
    3. de Moor JS,
    4. Ekwueme DU,
    5. Virgo KS,
    6. Kent EE,
    7. et al.
    For working-age cancer survivors, medical debt and bankruptcy create financial hardships. Health Aff 2016;35:54–61.
    OpenUrlAbstract/FREE Full Text
  22. 22.↵
    The Federal Reserve System. Report on the economic well-being of U.S. households in 2017. Available from: https://www.federalreserve.gov/publications/files/2017-report-economic-well-being-us-households-201805.pdf.
PreviousNext
Back to top
Cancer Epidemiology Biomarkers & Prevention: 30 (4)
April 2021
Volume 30, Issue 4
  • Table of Contents
  • Table of Contents (PDF)
  • Editorial Board (PDF)

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Epidemiology, Biomarkers & Prevention article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Improving the Process of Screening for Medical Financial Hardship in Oncology Practice
(Your Name) has forwarded a page to you from Cancer Epidemiology, Biomarkers & Prevention
(Your Name) thought you would be interested in this article in Cancer Epidemiology, Biomarkers & Prevention.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Improving the Process of Screening for Medical Financial Hardship in Oncology Practice
K. Robin Yabroff, Cathy J. Bradley and Ya-Chen Tina Shih
Cancer Epidemiol Biomarkers Prev April 1 2021 (30) (4) 593-596; DOI: 10.1158/1055-9965.EPI-21-0111

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Improving the Process of Screening for Medical Financial Hardship in Oncology Practice
K. Robin Yabroff, Cathy J. Bradley and Ya-Chen Tina Shih
Cancer Epidemiol Biomarkers Prev April 1 2021 (30) (4) 593-596; DOI: 10.1158/1055-9965.EPI-21-0111
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Authors' Disclosures
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Less Is More—Improved Breast Cancer Risk Stratification
  • Breast Tissue Composition - Why It Matters
Show more Commentaries
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Epidemiology, Biomarkers & Prevention

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Epidemiology, Biomarkers & Prevention
eISSN: 1538-7755
ISSN: 1055-9965

Advertisement